Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 13/20 | 0.63 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.53 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.53 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7050796 | 0.87 | GRIA4 (0.54) | GRIA4GRIA2GRIA1GRIA3MEN1 | |
| SCHEMBL7026830 | 0.84 | GRIA4 (0.74) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5877971 | 0.82 | GRIA4 (0.66) | GRIA4GRIA2GRIA1GRIA3MEN1 | |
| SCHEMBL5878346 | 0.80 | GRIA4 (0.60) | GRIA4GRIA2GRIA1GRIA3ALDH1A1 | |
| SCHEMBL6556293 | 0.80 | GRIA4 (0.60) | GRIA4GRIA2GRIA1GRIA3ALDH1A1 | |
| SCHEMBL13255761 | 0.79 | GRIA4 (0.87) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5992693 | 0.79 | GRIA4 (0.87) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6940515 | 0.79 | MAPT (0.51) | GRIA4MEN1POLBKMT2AMAPT | |
| SCHEMBL5877988 | 0.78 | GRIA4 (1.00) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL7028294 | 0.78 | MAPT (0.52) | GRIA4MEN1POLBKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225127-A1 | Heterocyclic sulfonamide derivatives | BENDER DAVID MICHAEL (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225127-A1 | Heterocyclic sulfonamide derivatives | GRIN2A, GRIN2B, GRIN1 | GRIA4 12/4885GRIA2 4/4885GRIA1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.